Surgery Partners, Inc.
NASDAQ:SGRYMedical - Care Facilities
+$0.06 today
- Market cap
- $3.53B
- Beta
- 1.95
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.59
Volume 3.24M
Average 1.36M
SGRY Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Surgery Partners, Inc.NASDAQ: SGRY
Gross Margin · Q3 FY2026 · quarter ended Sep 2026
Gross margin narrows to 22.7%
Gross margin was 22.7% in Q3 FY2026, down 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 21.1%, down 2.8 pp year over year. Over 3 fiscal years it widened by 0.5 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 23.1%
- Year-over-year change
- -0.8pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.1% | -0.8pp |
| FY2024 | 2024-12-31 | 23.9% | +0.3pp |
| FY2023 | 2023-12-31 | 23.6% | +1.0pp |
| FY2022 | 2022-12-31 | 22.6% | +0.6pp |
| FY2021 | 2021-12-31 | 22.1% | — |
Gross Margin vs competitors
How SGRY compares with its peers on the latest reported figures
- SGRY's LTM Sep 2026 gross margin of 21.1% is the lowest of the 7 companies compared; the peer median is 48.6%.
- Its year-over-year change of -2.8 pp is the 4th highest of 7, against a peer median of -6.9 pp.
- Over three fiscal years its change of +0.5 pp compares with a peer median of +9.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 90.7% | +0.5 pp | +1.4 pp | |
| LTM Mar 2026 | 53.7% | +11.9 pp | -31.5 pp | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | 49.7% | -26.6 pp | +16.2 pp |
| LTM Mar 2026 | 47.5% | -1.3 pp | +43.7 pp | |
| LTM Jun 2026 | 28.4% | -12.5 pp | +3.0 pp | |
| LTM Jun 2026 | 26.9% | -34.6 pp | +45.5 pp | |
| LTM Sep 2026 | 21.1% | -2.8 pp | +0.5 pp | |
| Peer median (excluding SGRY) | 48.6% | -6.9 pp | +9.6 pp | |
Competitors are the stored peer set for SGRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.23B | 2.54B | 2.74B | 3.11B | 3.31B |
| Cost of Revenue | 1.73B | 1.96B | 2.1B | 2.37B | 2.54B |
| Gross Profit | 491.4M | 574.9M | 647.5M | 745.6M | 765M |
| Gross Margin | 22.1% | 22.6% | 23.6% | 23.9% | 23.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 104M | 102.2M | 120.9M | 138.7M | 522.7M |
| Operating Expenses | 189.2M | 229.7M | 319.5M | 396.8M | 375.5M |
| Depreciation & Amortization | 98.8M | 114.8M | 118.1M | 152.6M | 176M |
| EBITDA | 401M | 460M | 446.1M | 501.4M | 565.5M |
| EBITDA Margin | 18.0% | 18.1% | 16.3% | 16.1% | 17.1% |
| Operating Income | 302.2M | 345.2M | 328M | 348.8M | 389.5M |
| Operating Margin | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 221M | 234.9M | 193M | 201.7M | 272.6M |
| Other Income / Expenses | (221M) | (234.9M) | (193M) | (201.7M) | (272.6M) |
| Income Before Tax | 81.2M | 110.3M | 135M | 147.1M | 116.9M |
| Pre-Tax Margin | 3.6% | 4.3% | 4.9% | 4.7% | 3.5% |
| Income Tax Expense | 10.5M | 23.3M | (300K) | 134.6M | 18M |
| Net Income | (70.9M) | (54.6M) | (11.9M) | (168.1M) | (77.9M) |
| Net Margin | -3.2% | -2.2% | -0.4% | -5.4% | -2.4% |
| EPS (Basic) | (1.12) | (0.59) | (0.09) | (1.33) | (0.61) |
| EPS (Diluted) | (1.12) | (0.59) | (0.09) | (1.33) | (0.61) |
| Weighted Avg Shares | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M |
| Weighted Avg Shares (Diluted) | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M |
Surgery Partners, Inc.
NASDAQ:SGRY
Intrinsic Alpha fair value
Locked
Current Price
$26.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.